FOLH1 and neoplasm: Nonetheless, the clinical studies further validate PSMA as a therapeutic target in mCRPC, and future development of ADCs may focus on improving synthetic linkers that limit deconjugation of the chemotherapeutic payload outside of the tumor microenvironment.